Natpar (Parathyroid Hormone)

Parathyroid hormone binds to PTH1 receptors on bone, kidney, and intestinal cells. This activation stimulates bone resorption to release calcium, increases renal tubular reabsorption of calcium, and promotes activation of vitamin D, which enhances intestinal calcium absorption, collectively raising blood calcium to normal ranges.

The dosing regimen for Natpar is individualized. A qualified prescriber determines the appropriate dose, frequency, and titration based on the patient’s serum calcium levels, clinical response, and overall health status. Specific dosing information should be obtained from the prescribing healthcare professional.

Safety data for Natpar in pregnancy and lactation are limited. The product’s pregnancy category is unknown, and it should only be used if the potential benefit justifies any potential risk to the fetus or infant. Clinicians should discuss risks and alternatives with the patient.

To request Natpar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

The primary alternatives for hypoparathyroidism are active vitamin D analogues (e.g., calcitriol) and oral calcium supplements. Unlike those agents, Natpar directly replaces deficient parathyroid hormone, offering more precise control of calcium homeostasis. However, it requires subcutaneous injection and cold‑chain handling, whereas oral agents are easier to administer.

Natpar must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If temperature excursions occur, discard the product according to the supplier’s stability guidelines.

Natpar is administered as a subcutaneous injection, typically into the abdomen or thigh. The solution is supplied ready‑to‑use; if reconstitution is required, follow the manufacturer’s instructions using aseptic technique. Injections are performed by a qualified healthcare professional or trained patient under supervision.

Serious risks include severe hypercalcemia, which can cause cardiac arrhythmias, renal impairment, or neurological symptoms; hypersensitivity reactions such as anaphylaxis; and, rarely, osteosarcoma. Patients should be monitored regularly for calcium levels and any signs of allergic response or bone pain.

Natpar is contraindicated in individuals with known hypersensitivity to parathyroid hormone or any excipients, patients with active hyperparathyroidism, severe hypercalcemia, or uncontrolled renal disease. Caution is also advised for those with a history of osteosarcoma or other bone malignancies.